Search Results

Emerging drugs for insomnia: new frontiers for old and novel targets

Authors: Sullivan, Shannon S; Guilleminault, Christian

Source: Expert Opinion on Emerging Drugs, Volume 14, Number 3, September 2009 , pp. 411-422(12)

Publisher: Informa Healthcare

Differential effects of acute and repeat dosing with the H₃ antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox−/− mice

Authors: Guo, RX; Anaclet, C; Roberts, JC; Parmentier, R; Zhang, M; Guidon, G; Buda, C; Sastre, JP; Feng, JQ; Franco, P; Brown, SH; Upton, N; Medhurst, AD; Lin, JS

Source: British Journal of Pharmacology, Volume 157, Number 1, May 2009 , pp. 104-117(14)

Publisher: Blackwell Publishing

Orexin Receptor Antagonism: A New Principle in Neuroscience

Authors: Boss, Christoph; Brisbare-Roch, Catherine; Jenck, Francois; Aissaoui, Hamed; Koberstein, Ralf; Sifferlen, Thierry; Weller, Thomas

Source: CHIMIA International Journal for Chemistry, Volume 62, Number 12, December 2008 , pp. 974-979(6)

Publisher: Swiss Chemical Society

Orexin Receptor Antagonists: Medicinal Chemistry and Therapeutic Potential

Authors: Roecker, Anthony J.; Coleman, Paul J.

Source: Current Topics in Medicinal Chemistry, Volume 8, Number 11, July 2008 , pp. 977-987(11)

Publisher: Bentham Science Publishers

The hypocretin/orexin receptor: therapeutic prospective in sleep disorders

Author: Nishino, Seiji

Source: Expert Opinion on Investigational Drugs, Volume 16, Number 11, November 2007 , pp. 1785-1797(13)

Publisher: Informa Healthcare

Orphan G-Protein-Coupled Receptors: Strategies for Identifying Ligands and Potential for Use in Eating Disorders

Authors: Harrold, Joanne A.; Halford, Jason C.G.

Source: Drugs in R&D, Volume 8, Number 5, 2007 , pp. 287-299(13)

Publisher: Adis International

The Type 2 Corticotrophin-Releasing Hormone Receptor Mediates Orexin A-Induced Luteinising Hormone Suppression in Ovariectomised Rats

Authors: Iwasa, T.; Matsuzaki, T.; Kiyokawa, M.; Shimizu, F.; Minakuchi, M.; Kuwahara, A.; Maegawa, M.; Yasui, T.; Irahara, M.

Source: Journal of Neuroendocrinology, Volume 19, Number 9, September 2007 , pp. 732-738(7)

Publisher: Blackwell Publishing

The Melanocortin System as a Therapeutic Treatment Target for Adiposity and Adiposopathy

Author: Bays, Harold

Source: Drugs in R&D, Volume 7, Number 5, 2006 , pp. 289-302(14)

Publisher: Adis International

Emerging drugs for eating disorder treatment

Authors: Steffen, Kristine J; Roerig, James L; Mitchell, James E; Uppala, Saritha

Source: Expert Opinion on Emerging Drugs, Volume 11, Number 2, May 2006 , pp. 315-336(22)

Publisher: Informa Healthcare

Antagonists of the orexin receptors

Authors: Cai, Jiaqiang; Cooke, Fiona E; Sherborne, Bradley S

Source: Expert Opinion on Therapeutic Patents, Volume 16, Number 5, May 2006 , pp. 631-646(16)

Publisher: Informa Healthcare

Dopaminergic regulation of orexin neurons

Authors: Bubser, Michael; Fadel, Jim R.; Jackson, Lela L.; Meador-Woodruff, James H.; Jing, Deqiang; Deutch, Ariel Y.

Source: European Journal of Neuroscience, Volume 21, Number 11, June 2005 , pp. 2993-3001(9)

Publisher: Blackwell Publishing

Tetrahydroisoquinolines as Orexin Receptor Antagonists: Strategies for Lead Optimization by Solution-Phase Chemistry

Authors: Koberstein, Ralf; Aissaoui, Hamed; Bur, Daniel; Clozel, Martine; Fischli, Walter; Jenck, François; Mueller, Celia; Nayler, Oliver; Sifferlen, Thierry; Treiber, Alexander; Weller, Thomas

Source: CHIMIA International Journal for Chemistry, Volume 57, Number 5, May 2003 , pp. 270-275(6)

Publisher: Swiss Chemical Society

N-Acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: The first orexin-2 receptor selective non-peptidic antagonist

Authors: Hirose M.; Egashira S.-i.; Goto Y.; Hashihayata T.; Ohtake N.; Iwaasa H.; Hata M.; Fukami T.; Kanatani A.; Yamada K.

Source: Bioorganic and Medicinal Chemistry Letters, Volume 13, Number 24, 15 December 2003 , pp. 4497-4499(3)

Publisher: Elsevier

Involvement of cholinergic neurons in orexin-induced contraction of guinea pig ileum

Authors: Matsuo K.; Kaibara M.; Uezono Y.; Hayashi H.; Taniyama K.; Nakane Y.

Source: European Journal of Pharmacology, Volume 452, Number 1, 27 September 2002 , pp. 105-109(5)

Publisher: Elsevier

Increased cortical expression of the orexin-1 receptor following permanent middle cerebral artery occlusion in the rat

Authors: Irving E.A.; Harrison D.C.; Babbs A.J.; Mayes A.C.; Campbell C.A.; Hunter A.J.; Upton N.; Parsons A.A.

Source: Neuroscience Letters, Volume 324, Number 1, 10 May 2002 , pp. 53-56(4)

Publisher: Elsevier

The action of orexin A on passive avoidance learning. Involvement of transmitters

Authors: Telegdy G.; Adamik A.

Source: Regulatory Peptides, Volume 104, Number 1, 15 March 2002 , pp. 105-110(6)

Publisher: Elsevier

Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice

Authors: Haynes A.C.; Chapman H.; Taylor C.; Moore G.B.T.; Cawthorne M.A.; Tadayyon M.; Clapham J.C.; Arch J.R.S.

Source: Regulatory Peptides, Volume 104, Number 1, 15 March 2002 , pp. 153-159(7)

Publisher: Elsevier

Orexin-A, an hypothalamic peptide with analgesic properties. (SmithKline Beecham Pharmaceuticals, Harlow, Essex, United Kingdom) Pain. 2001;92:81-90.

Authors: Bingham, S.; Davey, P. T.; Babbds, A. J.; Irving, E. A.; Sammons, M. J.; Wyles, M.; Jeffrey, P.; Cutler, L.; Riba, I.; Johns, A.; Porter, R. A.; Upton, N.; Hunter, A. J.; Parsons, A. A.

Source: Pain Practice, Volume 1, Number 4, December 2001 , pp. 375-375(1)

Publisher: Blackwell Publishing

Recent advances in feeding suppressing agents: potential therapeutic strategy for the treatment of obesity

Authors: Nakazato A.; Chaki S.

Source: Expert Opinion on Therapeutic Patents, Volume 11, Number 11, 1 November 2001 , pp. 1677-1692(16)

Publisher: Informa Healthcare

Interactions between orexin A, NPY and galanin in the control of food intake of the goldfish, Carassius auratus

Authors: Volkoff H.; Peter R.E.

Source: Regulatory Peptides, Volume 101, Number 1, 15 September 2001 , pp. 59-72(14)

Publisher: Elsevier